Notably, all four short variants of RB1 under LOH exhibited pCR, which is intriguing given a report demonstrating that RB1 loss is associated with tumors that are extremely sensitive to platinum retreatment in ovarian cancer [46]. Here, RB1 is linked to ovarian cancer.